"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...